[go: up one dir, main page]

ATE333879T1 - Zns-penetrierende nk-1 rezeptorantagonisten als antidepressivum und / oder anxiolytikum - Google Patents

Zns-penetrierende nk-1 rezeptorantagonisten als antidepressivum und / oder anxiolytikum

Info

Publication number
ATE333879T1
ATE333879T1 AT97944028T AT97944028T ATE333879T1 AT E333879 T1 ATE333879 T1 AT E333879T1 AT 97944028 T AT97944028 T AT 97944028T AT 97944028 T AT97944028 T AT 97944028T AT E333879 T1 ATE333879 T1 AT E333879T1
Authority
AT
Austria
Prior art keywords
antidepressant
receptor antagonists
anxiolytic
cns
penetrating
Prior art date
Application number
AT97944028T
Other languages
English (en)
Inventor
Emma Joanne Carlson
Nadia Melanie Rupniak
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9620880.6A external-priority patent/GB9620880D0/en
Priority claimed from GBGB9716460.2A external-priority patent/GB9716460D0/en
Priority claimed from GBGB9716458.6A external-priority patent/GB9716458D0/en
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE333879T1 publication Critical patent/ATE333879T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0463—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Optics & Photonics (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT97944028T 1996-10-07 1997-10-07 Zns-penetrierende nk-1 rezeptorantagonisten als antidepressivum und / oder anxiolytikum ATE333879T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9620880.6A GB9620880D0 (en) 1996-10-07 1996-10-07 Therapeutic use
GBGB9716460.2A GB9716460D0 (en) 1997-08-04 1997-08-04 In vivo assay
GBGB9716458.6A GB9716458D0 (en) 1997-08-04 1997-08-04 In vivo assay

Publications (1)

Publication Number Publication Date
ATE333879T1 true ATE333879T1 (de) 2006-08-15

Family

ID=27268509

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97944028T ATE333879T1 (de) 1996-10-07 1997-10-07 Zns-penetrierende nk-1 rezeptorantagonisten als antidepressivum und / oder anxiolytikum

Country Status (8)

Country Link
EP (1) EP0929303B1 (de)
JP (1) JP2001502311A (de)
AT (1) ATE333879T1 (de)
AU (1) AU726745B2 (de)
CA (1) CA2266773A1 (de)
DE (1) DE69736390T2 (de)
ES (1) ES2267153T3 (de)
WO (1) WO1998015277A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117855A (en) 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
AU738047B2 (en) * 1997-08-04 2001-09-06 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating mania
AU4278199A (en) * 1998-06-11 1999-12-30 Merck Sharp & Dohme Limited Use of a nk-1 receptor antagonist for treating psychiatric disorders
GB9812617D0 (en) * 1998-06-11 1998-08-12 Merck Sharp & Dohme Therapeutic use
AP2002002501A0 (en) * 1999-10-07 2002-06-30 Warner Lambert Co Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.
CA2324813A1 (en) * 1999-11-10 2001-05-10 Susan Beth Sobolov-Jaynes Combination treatment for depression and anxiety
US20020049211A1 (en) * 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
EP1192952A3 (de) * 2000-09-28 2003-03-26 Pfizer Products Inc. Ein NK-3 rezeptorantagonisten und ein ZNS-penetrierende NK-1 rezeptorantagonisten enthaltende Zusammensetzung zur Behandlung von Depression und Angst
WO2003009848A1 (en) * 2001-07-20 2003-02-06 Pfizer Products Inc. Use of nk-1 receptor antagonists to modify unwanted behavior in dogs, cats and horses
US20040006135A1 (en) * 2002-06-19 2004-01-08 Pfizer Inc. Combination treatment for depression and anxiety
SI1631557T1 (sl) * 2003-06-12 2007-06-30 Btg Int Ltd Cikličen hidroksilamin kot psihoaktivne spojine
JP4959336B2 (ja) * 2003-10-24 2012-06-20 イーライ リリー アンド カンパニー ｛２−［１−（３，５−ビストリフルオロメチルベンジル）−５−ピリジン−４−イル−１ｈ−［１，２，３］トリアゾル−４−イル］−ピリジン−３−イル｝−（２−クロロフェニル）−メタノンの新規の結晶形態
US9505728B2 (en) 2012-03-09 2016-11-29 Inception 2, Inc. Triazolone compounds and uses thereof
CN104918922B (zh) 2012-12-20 2017-04-26 因森普深2公司 三唑酮化合物及其用途
WO2015035059A1 (en) 2013-09-06 2015-03-12 Inception 2, Inc. Triazolone compounds and uses thereof
MA49524A (fr) 2017-06-30 2021-05-26 Chase Therapeutics Corp Compositions d'antagoniste de nk-1 et méthodes destinées à être utilisées dans le traitement de la dépression

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL106142A (en) * 1992-06-29 1997-03-18 Merck & Co Inc Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them
MX9703988A (es) * 1994-12-12 1998-02-28 Omeros Med Sys Inc SOLUCIaN Y MÉTODO DE IRRIGACIaN PARA LA INHIBICIaN DEL DOLOR, LA INFLAMACIaN Y ES ESPASMO.
IL116323A0 (en) * 1994-12-13 1996-03-31 Sandoz Ag Tachykinin antagonists their preparation and pharmaceutical compositions containing them
AU4918796A (en) * 1995-02-10 1996-08-27 Eli Lilly And Company Methods of treating or preventing psychiatric disorders

Also Published As

Publication number Publication date
EP0929303B1 (de) 2006-07-26
WO1998015277A2 (en) 1998-04-16
AU726745B2 (en) 2000-11-16
JP2001502311A (ja) 2001-02-20
CA2266773A1 (en) 1998-04-16
ES2267153T3 (es) 2007-03-01
EP0929303A2 (de) 1999-07-21
AU4567397A (en) 1998-05-05
DE69736390T2 (de) 2007-07-26
WO1998015277A3 (en) 1998-05-22
DE69736390D1 (de) 2006-09-07

Similar Documents

Publication Publication Date Title
ATE333879T1 (de) Zns-penetrierende nk-1 rezeptorantagonisten als antidepressivum und / oder anxiolytikum
DE69616480D1 (de) Piperidinderivate als neurokininantagonisten
ATE200279T1 (de) Herstellung von 3,4,4-trisubstituiertem piperidinyl-n-alkylcarboxylaten und zwischenverbindungen, verwendbar als opioid antagonisten
ATE302005T1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
TR199700644T1 (xx) Serotonin-ili�kili sistemler �zerinde etkiye sahip bile�ikler.
DE69721008D1 (de) Bicyclische pyrimidine derivate und ihre verwendung als antikoagulantien
ATE302606T1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
HK1029595A1 (en) Cyclic antagonists of c5a receptors and g protein-coupled receptors
ES2136096T3 (es) 14-beta-hidroxi-10-desacetil-baccatina iii y sus derivados como agentes antitumorales.
DE69331190D1 (de) Überbrückte azabicyclische derivate als substanz p antagonisten
PT918774E (pt) Compostos moduladores do receptor para androgenio e metodos
DE69825048D1 (de) Analoga von duocarmycin and cc-1065
BR9510486A (pt) Compostos moduladores de receptores de esteróide e métodos
MX9302888A (es) 1,2,3,4-tetrahidroisoquinolinas substituidas con propiedades antagonistas del receptor de angiotensina ii.
ES2119174T3 (es) Azaciclos espiro-sustituidos como antagonistas de los receptores de las taquiquininas.
ATE390917T1 (de) Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten
DE69938786D1 (de) Die verwendung von peptiden von il-2 und peptid-derivaten als therapeutische wirkstoffe
ATE219068T1 (de) Naphtylamides als zentralnervensystemmittel
HU9600815D0 (en) Tetrahydropyridine-(or 4-hydroxypiperidine) alkylazoles having an affinity for sigma and/or 5htia receptors
TR199900318T2 (xx) IL-8 resept�r antagonistleri.
ATE259230T1 (de) Verwendung von vasopressin-antagonisten zur behandlung von störungen oder erkrankungen des innenohres
DK0800536T3 (da) Rekombinante IL-5 antagonister, der er nyttige til behandling af IL-5-medierede lidelser
DK0639275T3 (da) Hidtil ukendte GABAa-receptorundertyper og fremgangsmåder til screening af lægemiddelforbindelser under anvendelse af imidazoquinoxaliner og pyrrolopyimidiner til binding til GABAa-receptorundertyper
DK0989973T3 (da) Chalconer med antiproliferativ aktivitet
BR9803385A (pt) AtropisÈmeros de 2,3-dissubstituìdo-(5,6)-heteroaril condensado-pirimidin-4-onas.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties